Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease.
about
The status of pharmacotherapy for autism spectrum disordersComparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's diseaseThe lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesPotential antidepressive properties of amantadine, memantine and bifemelane.Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.Extra-vesicular binding of noradrenaline and guanethidine in the adrenergic neurones of the rat heart: a proposed site of action of adrenergic neurone blocking agentsControl of influenza: when do I use amantadine?Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.The effects of blocking catecholamine uptake on amphetamine-induced circling behaviour in mice with unilateral destruction of striatal dopaminergic nerve terminals.Effect of chronic drug treatment on intestinal membrane transport of 14 C-L-dopaResponses of neurones in the cerebral cortex and caudate nucleus to amantadine, amphetamine and dopamine.Studies on the mechanism of action of amantadine.The role of dopamine and noradrenaline in temperature control of normal and reserpine-pretreated mice.Hypothermic effect of apomorphine in the mouse.Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient.Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).Modulation of human motor cortex excitability by single doses of amantadine.Proceedings: The effect of amantadine on the turnover of catecholamines in the rat brain.Psychoactive properties of amantadine.Interaction of apomorphine and amantadine with ethanol in men.
P2860
Q28239931-C8955510-CA0E-4625-87D4-A188D356B7E0Q28364195-49B0E195-4DF4-45E9-B977-447674A2B9BFQ34329204-20D288C8-9C8E-4653-9CB1-E580EB6EEA03Q34353745-1B7A7465-4B2E-4ECD-A10F-4D5C0556449CQ34515375-0247894F-9BAE-4ED0-A797-FD99FA2B4054Q35176613-FEF5E120-3690-4CEE-A7EF-BFE768097416Q36521225-65140F7F-9419-463C-9D33-5D26561E732BQ38285126-270087B4-712F-401D-A480-1CECCFFDF25DQ39104145-01073569-CDED-4A86-B5F9-940C1D658F81Q39999442-1B895D2C-91BE-4EF7-ABC5-3D701C2E7D8CQ40008337-109D6CE6-221F-489A-9643-5C306A068A9CQ40026451-00659887-FB38-4B03-88E0-B7DC0810F361Q40333884-AB4E9829-213B-4BF5-84DB-8F3CCDFD5839Q43455283-78BE4278-2DB0-4739-B78F-42AE936D2BE2Q44335608-EC73702E-2180-4A7D-96F9-4F379D67D354Q46641045-01C78BF8-2BC7-4DF5-ADC0-14ABAD54C789Q48489411-151087F8-FA26-4320-872B-4B6FA1EF3AC5Q48504404-9B5C0383-49C2-4FE8-87C8-FF88A5769BF1Q51226475-B6572DD2-6943-4F3B-8A67-2592C43C8381Q51252333-3FB1896A-C85F-4023-8E21-DED6665DB622
P2860
Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease.
description
1971 nî lūn-bûn
@nan
1971年の論文
@ja
1971年学术文章
@wuu
1971年学术文章
@zh
1971年学术文章
@zh-cn
1971年学术文章
@zh-hans
1971年学术文章
@zh-my
1971年学术文章
@zh-sg
1971年學術文章
@yue
1971年學術文章
@zh-hant
name
Dopamine and noradrenaline rel ...... action in Parkinson's disease.
@en
Dopamine and noradrenaline rel ...... action in Parkinson's disease.
@nl
type
label
Dopamine and noradrenaline rel ...... action in Parkinson's disease.
@en
Dopamine and noradrenaline rel ...... action in Parkinson's disease.
@nl
prefLabel
Dopamine and noradrenaline rel ...... action in Parkinson's disease.
@en
Dopamine and noradrenaline rel ...... action in Parkinson's disease.
@nl
P2093
P1476
Dopamine and noradrenaline rel ...... action in Parkinson's disease.
@en
P2093
Farnebo LO
Goldstein M
Hamberger B
Ungerstedt U
P356
10.1016/0014-2999(71)90053-7
P407
P50
P577
1971-09-01T00:00:00Z